Therapeutic Antibodies in Cancer Treatment in the UK

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Dec 11

PMID 36498915

Authors

Khadiga Eltarhoni

Faddy Kamel

Katrina Ihebunezie

Pasha Nisar

Mikhail Soloviev

Affiliations

Soon will be listed here.

Abstract

The growing understanding of the molecular mechanisms of carcinogenesis accelerated the development of monoclonal therapeutic antibodies to specifically target multiple cancer pathways. Recombinant protein therapeutics now constitute a large proportion of yearly approved medicines. Oncology, autoimmune diseases and to a smaller degree the prophylaxis of organ transplant rejection are their main application areas. As of the date of this review, 37 monoclonal antibody products are approved for use in cancer treatments in the United Kingdom. Currently, the antibody therapeutics market is dominated by monoclonal immunoglobulins (IgGs). New types of recombinant antibody therapeutics developed more recently include bispecific recombinant antibodies and other recombinantly produced functional proteins. This review focuses on the approved therapeutic antibodies used in cancer treatment in the UK today and describes their antigen targets and molecular mechanisms involved. We provide convenient links to the relevant databases and other relevant resources for all antigens and antibodies mentioned. This review provides a comprehensive summary of the different monoclonal antibodies that are currently in clinical use primarily in malignancy, including their function, which is of importance to those in the medical field and allied specialties.

Citing Articles

State-of-the-Art Molecular Oncology in UK.

Sandoughdaran S, Mikropoulos C, Boussios S Int J Mol Sci. 2023; 24(11).

PMID: 37298288 PMC: 10252995. DOI: 10.3390/ijms24119336.

References

Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

Scott L . Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. Drugs. 2017; 77(4):435-445. PMC: 7102329. DOI: 10.1007/s40265-017-0705-5. View

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

Kim Y, Bagot M, Pinter-Brown L, Rook A, Porcu P, Horwitz S . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(9):1192-1204. DOI: 10.1016/S1470-2045(18)30379-6. View

Mitsudomi T, Yatabe Y . Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98(12):1817-24. PMC: 11159145. DOI: 10.1111/j.1349-7006.2007.00607.x. View

Salles G, Barrett M, Foa R, Maurer J, OBrien S, Valente N . Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017; 34(10):2232-2273. PMC: 5656728. DOI: 10.1007/s12325-017-0612-x. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Dhillon S . Isatuximab: First Approval. Drugs. 2020; 80(9):905-912. DOI: 10.1007/s40265-020-01311-1. View

Piha-Paul S, Oh D, Ueno M, Malka D, Chung H, Nagrial A . Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020; 147(8):2190-2198. DOI: 10.1002/ijc.33013. View

10.

McCafferty J, Griffiths A, Winter G, Chiswell D . Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990; 348(6301):552-4. DOI: 10.1038/348552a0. View

11.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

12.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

13.

Kasherman L, Ahrari S, Lheureux S . Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2020; 17(8):877-892. DOI: 10.2217/fon-2020-0655. View

14.

Rosen L, Jacobs I, Burkes R . Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017; 12(5):599-610. PMC: 5610666. DOI: 10.1007/s11523-017-0518-1. View

15.

Mayadev J, Nunes A, Li M, Marcovitz M, Lanasa M, Monk B . CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020; 30(7):1065-1070. PMC: 7398223. DOI: 10.1136/ijgc-2019-001135. View

16.

Abd El-Rehim D, Pinder S, Paish C, Bell J, Rampaul R, Blamey R . Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004; 91(8):1532-42. PMC: 2410019. DOI: 10.1038/sj.bjc.6602184. View

17.

Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J . A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2021; 112(7):2845-2854. PMC: 8253277. DOI: 10.1111/cas.14937. View

18.

McDougall A, Tolcos M, Hooper S, Cole T, Wallace M . Trop2: from development to disease. Dev Dyn. 2014; 244(2):99-109. DOI: 10.1002/dvdy.24242. View

19.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

20.

OKane G, Bradbury P, Feld R, Leighl N, Liu G, Pisters K . Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017; 109:137-144. DOI: 10.1016/j.lungcan.2017.04.016. View